Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 1999

View Archived Issues

Lorus Therapeutics announces preclinical data on anticancer compound

Ilex Oncology focuses on anticancer drugs

Micrologix Biotech continues preclinical testing on acne drugs

Genelabs Technologies' DARPA drug discovery grant renewed

Gastric antisecretory and gastroprotective compounds in development at Byk Gulden

Merck researchers design tachykinin antagonists particularly useful as antiemetics

FDA awards fast track designation to Trimeris's HIV fusion inhibitor

Antiulcer benzimidazoles discovered by Dr. Reddy's group

Novartis describes new PNP inhibitor series in recent patent literature

Purinoceptor P2 receptor antagonists in early development at Astra

Second-generation NNRTIs show promising resistance profile, pharmacokinetics in preclinical studies

Orphan Medical's Busulfex Injection approved in U.S.

Ex vivo studies explain disappointing results with antiadhesion therapy in stroke patients

Boston Life Sciences identifies a second antiangiogenic molecule

Lubeluzole shows good safety but no efficacy in large trial in acute stroke patients

Sch-217048: potent and selective neurokinin antagonist from natural sources

Ligand receives FDA approval for Ontak as CTCL treatment

Preclinical profile of novel antimigraine agent SB-220453 described

Emadine approved for conjunctivitis in Europe

UCB files NDA for levetiracetam

Kitasato investigators discover new microbial-based compound for atherosclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...